- Home
- SILA vs ARVN Comparison
SILA vs ARVN Comparison
Compare SILA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILA
- ARVN
- Stock Information
- Founded
- SILA 2013
- ARVN 2015
- Country
- SILA United States
- ARVN United States
- Employees
- SILA N/A
- ARVN N/A
- Industry
- SILA
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- SILA
- ARVN Health Care
- Exchange
- SILA NYSE
- ARVN Nasdaq
- Market Cap
- SILA 1.3B
- ARVN 1.4B
- IPO Year
- SILA N/A
- ARVN 2018
- Fundamental
- Price
- SILA $24.48
- ARVN $17.77
- Analyst Decision
- SILA Strong Buy
- ARVN Strong Buy
- Analyst Count
- SILA 3
- ARVN 12
- Target Price
- SILA $28.67
- ARVN $58.82
- AVG Volume (30 Days)
- SILA 321.3K
- ARVN 1.1M
- Earning Date
- SILA 02-25-2025
- ARVN 02-11-2025
- Dividend Yield
- SILA 3.27%
- ARVN N/A
- EPS Growth
- SILA N/A
- ARVN N/A
- EPS
- SILA 0.37
- ARVN N/A
- Revenue
- SILA $186,225,000.00
- ARVN $263,399,999.00
- Revenue This Year
- SILA N/A
- ARVN N/A
- Revenue Next Year
- SILA $4.55
- ARVN $1.63
- P/E Ratio
- SILA $66.26
- ARVN N/A
- Revenue Growth
- SILA N/A
- ARVN 235.54
- 52 Week Low
- SILA $20.20
- ARVN $16.61
- 52 Week High
- SILA $26.75
- ARVN $51.51
- Technical
- Relative Strength Index (RSI)
- SILA N/A
- ARVN 44.33
- Support Level
- SILA N/A
- ARVN $17.19
- Resistance Level
- SILA N/A
- ARVN $20.38
- Average True Range (ATR)
- SILA 0.00
- ARVN 1.38
- MACD
- SILA 0.00
- ARVN 0.08
- Stochastic Oscillator
- SILA 0.00
- ARVN 30.77
About SILA SILA REALTY TRUST INC
Sila Realty Trust Inc is a real estate investment trust. Its investment objective is to pay regular cash distributions to stockholders and to preserve, protect, and return capital contributions to stockholders. The company owns and manages healthcare assets. The company generates revenue from real estate investments in healthcare properties.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.